Use of methionine or a metabolite thereof in the manufacture of a medicament or nutritional supplement for the treatment of an immune-related disease

By supplementing with methionine or its metabolites such as SAM, T cell function is regulated, overcoming the adverse reactions and high costs of existing immunosuppressants, and achieving safe and effective treatment for transplant rejection and autoimmune diseases.

CN122140688APending Publication Date: 2026-06-05NANKAI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NANKAI UNIV
Filing Date
2024-12-05
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

Existing immunosuppressants have adverse reactions and high costs in treating allogeneic graft tolerance after transplantation. There is an urgent need for safe, effective and economical methods to regulate immune imbalance and reconstitute immune tolerance.

Method used

Using methionine or its metabolites such as S-adenosylmethionine (SAM) as the main active ingredient, drugs or nutritional supplements can be prepared by oral administration, injection, or topical application to regulate T cell function and inhibit transplant rejection and autoimmune diseases.

Benefits of technology

It significantly inhibits the expression of pro-inflammatory cytokines IFN-γ and GZMB, downregulates the proportion of effector memory T cells, prolongs graft survival time, improves immune tolerance, and reduces treatment costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122140688A_ABST
    Figure CN122140688A_ABST
Patent Text Reader

Abstract

The application relates to application of methionine or a metabolite thereof in preparation of a medicine or a nutritional supplement for treating an immune-related disease, which can be used for treating or assisting in treating immune rejection of transplantation or an autoimmune disease, and the methionine and the metabolite thereof can be used as main active ingredients of the medicine or the nutritional supplement alone or in cooperation, or can be used in combination with other ingredients. Intake of the methionine or the metabolite thereof can significantly inhibit expression of proinflammatory cytokines IFN-gamma and Granzyme B in spleen T cells, reduce a proportion of effector memory T cells, inhibit transplantation rejection, improve immune tolerance of the body, and reconstruct immune balance, thereby providing a new method for clinical organ transplantation and treatment of autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art